Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, according to results from the phase II eNRGy clinical trial presented at the AACR-NCI-EORTC International Conference on Molecular Targets, held October 22–26.
This article was originally published on MedicalXpress.com
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Microneedling is a revolutionary skincare treatment that has gained popularity in recent years due to its numerous benefits, including reducing the appearance of scars, wrinkles, and acne, and promoting collagen production. Edmonton, the bustling capital […]
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
© 2025 SimplyWell.ca